Topic: How To Invest

What is Pat’s commentary for the week of November 17, 2020

Article Excerpt

We continue to see attractive investment opportunities in drug stocks. COVID-19 gave it a boost, of course. But the industry was already going to prosper, thanks to ongoing regulatory and research developments. Still, due to the nature of the business, results will vary widely and unpredictably from one drug company to another. Merck & Co. is one pharmaceutical firm that stands out given its Keytruda blockbuster drug—one of the world’s best sellers—as well as the rest of its drug pipeline. The company is also streamlining its operations to boost profits. That includes spinning off some businesses to concentrate on its most promising therapies, vaccines and animal health products. I asked our TSI research team to draw up this Spotlight report on Merck for our Inner Circle members. We hope you enjoy and profit from it. Pat INNER CIRCLE SPOTLIGHT REPORT ON MERCK & CO.  Merck’s present and future are bright Merck & Co. Inc., $81.59, symbol MRK on New York (Shares outstanding: 2.5 billion; Market…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.